BS_D8N31T39
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 44.283837056504595
- age_years
- 0.378
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- TNFA_SIGNALING_VIA_NFKB+0.466
- ALLOGRAFT_REJECTION+0.451
- IL6_JAK_STAT3_SIGNALING+0.448
- ANGIOGENESIS+0.431
- INTERFERON_GAMMA_RESPONSE+0.429
- INFLAMMATORY_RESPONSE+0.414
- COAGULATION+0.413
- INTERFERON_ALPHA_RESPONSE+0.406
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.376
Top 10 suppressed
- PROTEIN_SECRETION-0.216
- SPERMATOGENESIS-0.161
- UV_RESPONSE_DN-0.147
- ANDROGEN_RESPONSE-0.126
- TGF_BETA_SIGNALING-0.126
- PANCREAS_BETA_CELLS-0.103
- OXIDATIVE_PHOSPHORYLATION-0.062
- HEDGEHOG_SIGNALING-0.055
- KRAS_SIGNALING_DN-0.022
- FATTY_ACID_METABOLISM+0.016
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A6TD-01A-51R-A33J-07 | — | — | 0.928 |
| 2 | BS_M85CXHDV | high-grade glioma | — | 0.904 |
| 3 | 25B5E54F-5858-454C-9B23-440A82450912 | — | — | 0.890 |
| 4 | 20050099.TNBC | — | D | 0.890 |
| 5 | TCGA-66-2765-01A-01R-0851-07 | — | cohortSQ1 | 0.886 |
| 6 | MNG256 | — | — | 0.882 |
| 7 | MDT-AP-1106 | Med | Medulloblastoma | 0.879 |
| 8 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.879 |
| 9 | 53018DE1-9557-4181-A0F2-5200013F1CEA | — | — | 0.878 |
| 10 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.466 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.451 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.448 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.431 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.429 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.414 | Idelalisib | — uncovered |
| COAGULATION | 0.413 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.406 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.376 | Inavolisib | — uncovered |
| COMPLEMENT | 0.363 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.358 | Inavolisib | — uncovered |
| APOPTOSIS | 0.319 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.295 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.293 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.261 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.257 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.257 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.244 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.239 | Idelalisib | — uncovered |